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Summary
Background The burden of inflammatory bowel disease (IBD) is rising globally, with substantial variation in levels and 
trends of disease in different countries and regions. Understanding these geographical differences is crucial for 
formulating effective strategies for preventing and treating IBD. We report the prevalence, mortality, and overall 
burden of IBD in 195 countries and territories between 1990 and 2017, based on data from the Global Burden of 
Diseases, Injuries, and Risk Factors Study (GBD) 2017.
Methods We modelled mortality due to IBD using a standard Cause of Death Ensemble model including data mainly 
from vital registrations. To estimate the non-fatal burden, we used data presented in primary studies, hospital 
discharges, and claims data, and used DisMod-MR 2.1, a Bayesian meta-regression tool, to ensure consistency 
between measures. Mortality, prevalence, years of life lost (YLLs) due to premature death, years lived with disability 
(YLDs), and disability-adjusted life-years (DALYs) were estimated. All of the estimates were reported as numbers and 
rates per 100 000 population, with 95% uncertainty intervals (UI).
Findings In 2017, there were 6·8 million (95% UI 6·4–7·3) cases of IBD globally. The age-standardised prevalence 
rate increased from 79·5 (75·9–83·5) per 100 000 population in 1990 to 84·3 (79·2–89·9) per 100 000 population in 
2017. The age-standardised death rate decreased from 0·61 (0·55–0·69) per 100 000 population in 1990 to 
0·51 (0·42–0·54) per 100 000 population in 2017. At the GBD regional level, the highest age-standardised prevalence 
rate in 2017 occurred in high-income North America (422·0 [398·7–446·1] per 100 000) and the lowest age-
standardised prevalence rates were observed in the Caribbean (6·7 [6·3–7·2] per 100 000 population). High Socio-
demographic Index (SDI) locations had the highest age-standardised prevalence rate, while low SDI regions had 
the lowest age-standardised prevalence rate. At the national level, the USA had the highest age-standardised 
prevalence rate (464·5 [438·6–490·9] per 100 000 population), followed by the UK (449·6 [420·6–481·6] per 
100 000). Vanuatu had the highest age-standardised death rate in 2017 (1·8 [0·8–3·2] per 100 000 population) and 
Singapore had the lowest (0·08 [0·06–0·14] per 100 000 population). The total YLDs attributed to IBD almost 
doubled over the study period, from 0·56 million (0·39–0·77) in 1990 to 1·02 million (0·71–1·38) in 2017. The age-
standardised rate of DALYs decreased from 26·5 (21·0–33·0) per 100 000 population in 1990 to 23·2 (19·1–27·8) 
per 100 000 population in 2017.
Interpretation The prevalence of IBD increased substantially in many regions from 1990 to 2017, which might pose a 
substantial social and economic burden on governments and health systems in the coming years. Our findings can 
be useful for policy makers developing strategies to tackle IBD, including the education of specialised personnel to 
address the burden of this complex disease.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license. 
Introduction
Inflammatory bowel disease (IBD) is characterised 
by non-infectious chronic inflammation of the 
gastrointestinal tract, and primarily includes Crohn’s 
disease (which can affect any segment of the 
gastrointestinal tract from the mouth to the anus), 
ulcerative colitis (which is limited to the colonic 
mucosa), and indeterminate colitis.1 Crohn’s disease 
and ulcerative colitis both commonly present with 
abdominal pain and diarrhoea. Rectal bleeding occurs 
more frequently with ulcerative colitis than with 
Crohn’s disease, but patients with Crohn’s disease often 
experience weight loss and perianal disease.2 The peak 
of IBD’s occurrence, followed by a chronic relapsing 
pattern, usually happens in the second to fourth decade 
of life, the most productive time of adulthood.1 IBD can 
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adversely affect all aspects of an individual’s life.1 
Although the cause of IBD is still not completely 
understood, IBD is suggested to be a result of 
uncontrolled immune response to a trigger in 
genetically prone individuals.1 The role of environmental 
factors either as the triggers or causes of the 
uncontrolled immune response continues to be 
debated.1
Traditionally, IBD has been regarded as a disease of 
high-income nations, but a shift in the epidemiological 
pattern has been reported, indicating stabilising inci-
dence in high-income countries with a high burden and 
prevalence, and a rapid rise in newly industrialised 
coun tries in South America, eastern Europe, Asia, and 
Africa.3 These rapid changes call for global estimates to 
provide insight into the burden and trends. Moreover, 
defining the varying incidence, prevalence, and 
prognosis of IBD in different geographical regions 
might provide researchers with clues to the cause of the 
disease.4
We report the IBD burden in 195 countries and terri-
tories from 1990 to 2017, based on the most recent Global 
Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) 2017 estimates in terms of prevalence, mortality, 
years lived with disability (YLDs), years of life lost (YLLs), 
and disability-adjusted life-years (DALYs).
Methods
Overview
This study is part of GBD 2017, which, to the best of our 
knowledge, is the most comprehensive and systematic 
effort to estimate the burden of diseases, injuries, and 
risk factors at global, regional, and national levels to 
date. GBD 2017 estimated 359 diseases and injuries; 
282 causes of death; and 84 behavioural, environmental 
and occupa tional, and metabolic risk factors. The 
detailed methods are published elsewhere.3,5,6
Crohn’s disease and ulcerative colitis (ie, the two types 
of IBD we investigated) are diagnosed by endoscopy, 
imaging studies, or biopsy in a patient with relevant 
clinical signs and symptoms. In some cases of IBD, 
neither Crohn’s disease nor ulcera tive colitis can be 
definitely diagnosed, and a diagnosis of indeterminate 
colitis is applied indefinitely or until defini tive features of 
Crohn’s disease or ulcerative colitis are identifiable.7 
Research in context
Evidence before this study
Inflammatory bowel disease (IBD) imposes health and 
economic burdens on communities worldwide, and 
substantially reduces patients’ quality of life. It is estimated that 
more than 3 million people in the USA and Europe have IBD, 
and its prevalence is estimated to exceed 0·3% in North 
America, Oceania, and many countries in Europe. Evidence 
from systematic reviews points to a changing epidemiology of 
IBD, with stable or decreasing incidence in North America and 
Europe, and increasing incidence in newly industrialised 
countries. Most of these studies have originated in high-
income countries, and countries with lower socioeconomic 
status have produced few, if any, population-based studies that 
report prevalence, incidence, or IBD-related deaths. These 
studies also do not include estimation over time and usually do 
not include estimates for years of life lost (YLLs), years lived 
with disability (YLDs), or disability-adjusted life-years (DALYs) 
across either countries or geographically related regions.
Added value of this study
The Global Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) 2017 used an integrated modelling approach to estimate 
not only the epidemiological parameters for regions with 
available data, but also for countries and territories, as well as 
regions in which sufficient data are not available. GBD 2017 
provided estimates of the burden of IBD for seven 
super-regions, 21 regions, and 195 countries and territories 
from 1990 to 2017. There has been no previous dedicated and 
detailed publication of GBD methods and estimates for IBD. 
We report the burden of IBD, including prevalence, mortality, 
YLDs, and DALYs, by age, sex, and Socio-demographic Index 
(SDI) from 1990 to 2017, using all available data and based on 
standardised GBD methods at the global, regional, and national 
levels. In addition to exploring country-level variation in the 
burden of IBD by development level, we assessed the temporal 
patterns and changes in geographical patterns of the burden of 
IBD. We believe this analysis is the most comprehensive picture 
of IBD burden to date.
Implication of all the available evidence
Between 1990 and 2017, the global number of prevalent cases 
of IBD increased. After many years of sharp increases in IBD 
incidence in North America and western European countries, 
and because of improved survival, a pattern of increased 
prevalence emerged in these regions. An alarming trend for 
health systems is the observed rise in prevalence in newly 
industrialised countries. The full effect of this rise might not yet 
have been fully appreciated, because IBD symptoms persist 
throughout life, producing prominent disability and morbidity. 
The information provided in this study could be crucial for 
researchers, clinicians, and health policy makers to prepare their 
clinical infrastructure and educate specialised personnel to be 
able to confront the burden of this complex, and socially and 
economically costly disease. Moreover, the rising pattern of IBD 
provides a unique opportunity for researchers to focus on 
identifying the environmental risk factors contributing to IBD.
Figure 1: (A) Age-standardised prevalence rate (per 100 000 population) of 
IBD, both sexes, for 195 countries and territories, 2017. (B) Percentage 
change in age-standardised prevalence rate (per 100 000 population) of 
IBD, both sexes, for 195 countries and territories, 1990–2017
IBD=inflammatory bowel disease. ATG=Antigua and Barbuda. VCT=Saint 
Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. 
TLS=Timor-Leste. FSM=Federated States of Micronesia.
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International Classification of Disease version 10 
(ICD-10) codes were K50 for Crohn’s disease, K51 for 
ulcerative colitis, and K52 for indeterminate colitis.
Mortality estimates
To model IBD mortality, we used the causes of death 
database, which includes data from vital registration and 
verbal autopsy data. The data processing for the causes of 
death data has been described previously.5 We marked 
data as outliers if garbage code redistribution and noise 
reduction in combina tion with small sample sizes 
resulted in un reason able cause fractions, as well as data 
that violated well-established time or age trends.
We modelled deaths due to IBD with a standard Cause 
of Death Ensemble model (CODEm), using the causes of 
death database and location-level covariates as inputs. We 
hybridised separate global and data-rich models for each 
sex to obtain unadjusted results. We then finalised and 
adjusted estimates to be consistent with all-cause 
mortality levels for each age–sex–year location using the 
cause of death correct procedure (CODCorrect) to reach 
final YLLs due to IBD.5 The method for propagating 
uncertainty was similar to that used in previous GBD 
papers.5 The distribution of every step in the computation 
process was stored in 1000 draws that were used for every 
other step in the process. Final estim ates were computed 
using the mean estimate across 1000 draws, and the 
95% uncertainty intervals (UIs) were specified on the 
basis of the 25th and 975th ranked values across all 
1000 draws.
The percentage change between any 2 years of estimates 
in GBD was calculated at the draw level. Every one of 
1000 draws for 2017 was compared with the corresponding 
draw for 1990 to generate 1000 percent change draws. The 
mean of the draws and the 25th and 975th ordered draws 
were then used as the mean, lower UI limit, and upper UI 
limit for reporting the percentage change.
Non-fatal estimates
To estimate the non-fatal burden of IBD, we used 
two separate databases, one for Crohn’s disease and 
another for ulcerative colitis. Both included data from 
literature, hospital discharges, and claims data (the 
latter available only from the USA in 2000, 2010, and 
2012; further information on IBD data is provided in 
the appendix, p 21). Claims data link multiple inpatient 
and outpatient claims to a single individual; prevalent 
cases were extracted if an individual had at least one 
inpatient or outpatient encounter with an appropriate 
ICD code as any diagnosis. Data from hospital 
discharges were adjusted using correction factors from 
claims, converting encounters to estimates of cases, 
correcting for some facilities providing only primary 
diagnostic codes, and estimating outpatient cases from 
inpatient cases. Literature data came from a systematic 
review done for GBD 2016.8 In brief, this systematic 
Figure 2: Trends from 1990 to 2017 in number and age-standardised prevalence rates of IBD at the global level
Error bars indicate the 95% uncertainty interval (UI) for prevalent cases. Shading indicates the 95% UI for the age-standardised prevelance rate. IBD=inflammatory bowel disease.
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review of literature was done to capture studies of the 
prevalence and incidence of IBD. Studies were excluded 
if they were not representative of the national 
population, or if they had insufficient or inappropriate 
sampling methods. Reviews were excluded from the 
search results.
The prevalence and incidence data described earlier 
were entered into separate models for ulcerative colitis 
and Crohn’s disease in DisMod-MR 2.1, a Bayesian meta-
regression tool, as the main method of estimation, 
ensuring consistency between rates of prevalence, inci-
dence, remission, and cause of death for each non-fatal 
condition. Outputs from DisMod were then adjusted to 
account for IBD due to indeterminate colitis.
For both ulcerative colitis and Crohn’s disease, the 
DisMod models used prevalence and incidence data, 
as described above. Reference data were claims from 
the USA from 2012, and study-level covariates were used 
to mark data from literature, hospital discharges, US 
claims in 2000 and 2010, and the Medical Expenditure 
Panel Survey. The study-level covariate for hospital 
discharges for Crohn’s disease was found to have no 
significant effect and was later dropped during data 
analysis. For ulcerative colitis, a prior value on remission 
was set to zero for all age groups, and an incidence prior 
value was set to zero only for ages zero to 1 year. For 
Crohn’s disease, a prior value on remission was set to 
zero for all age groups, and on incidence a prior value 
was set to zero only for ages zero to 2 years. Location-
level covariates were log-transformed lag-distributed 
income and Healthcare Access and Quality Index (both 
on excess mortality) and log-transformed age-
standardised death rate due to both types of IBD (on 
prevalence).
The proportion of IBD cases categorised as indeter-
minate colitis was determined to be 0·624 (95% UI 
0·0549–0·0699) via meta-analysis. To account for all IBD 
cases, an adjustment of 1·0624 (1·0549–1·0699) was 
applied to the outputs of our ulcerative colitis and Crohn’s 
disease models. This approach assumes that all cases 
initially diagnosed as indeterminant ultimately declare 
themselves to be one of these two defined diseases.
Estimates of prevalence were combined with disability 
weights to estimate YLDs. The basis of the GBD disability 
weight survey assessments are lay descriptions of 
sequelae highlighting major functional consequences 
and sympt oms. For GBD 2017, we used the Medical 
Expenditure Panel Survey to find the proportion 
of ulcerative colitis and Crohn’s disease that was 
asymptomatic versus sympto matic during a given 4-week 
period. The lay des cription for either of these diseases in 
case they were symptomatic was defined as a person who 
has cramping abdominal pain, has diarrhoea several 
times a day, and feels very tired for 2 months every year, 
and when the person does not have symptoms, there is 
anxiety about them returning. The disability weight for 
symptomatic Crohn’s disease and ulcerative colitis was 
0·231 (95% UI 0·156–0·320).
We estimated the burden of IBD in terms of mortality, 
prevalence, YLLs, YLDs, and DALYs, which are the sum 
Figure 3: Age patterns by sex in 2017 of the total number of prevalent cases and age-specific prevalence rate of IBD at the global level
IBD=inflammatory bowel disease.
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of YLLs and YLDs, for both sexes, 20 age groups, and 
195 countries and territories from 1990 to 2017. The rates 
were age-standardised according to the GBD world 
population and are reported per 100 000 population.9 
95% UIs were reported for all estimates. This study is 
compliant with the Guidelines for Accurate and 
Transparent Health Estimates Reporting.
Role of the funding source
The funder of the study had no role in study design; the 
collection, analysis, or interpretation of the data; or the 
writing of the report. The corresponding author had full 
access to all of the data and the final responsibility to 
submit for publication.
Results
Between 1990 and 2017, the number of individuals with 
IBD increased from 3·7 million (95% UI 3·5–3·9) to more 
than 6·8 million (6·4–7·3), an increase of 85·1% 
(79·5–89·9) in global prevalent cases of IBD 
(appendix p 22). However, the global age-standardised pre-
valence rate of IBD showed only a 6·1% (3·3–8·6) increase, 
from 79·5 (75·9–83·5) per 100 000 population in 1990 to 
84·3 (79·2–89·9) per 100 000 population in 2017. The global 
map of age-standardised prevalence rate of IBD and 
percentage change in age-standardised prevalence at the 
country level are presented in figure 1. Both the number of 
prevalent cases and age-standardised prevalence rate were 
significantly higher in females than males in all years from 
1990 to 2017 (figure 2). Overall, nearly 3·9 million (3·6–4·1) 
prevalent cases (57%) occurred among females in 2017, 
and nearly 3·0 million (2·8–3·2) cases (43%) occurred in 
males. The age-standardised prevalence rate was 
75·0 (70·3–79·7) per 100 000 population in males and 
93·8 (87·8–100·0) per 100 000 population in females in 
2017. The highest peak of IBD age-specific prevalence rate 
occurred at age 60–64 years in females, whereas the peak 
was at age 70–74 years in males (figure 3).
The total number of IBD-related deaths increased 
by 67·0% (95% UI 23·6–96·1) from 1990 to 2017, 
from 23 000 (20 000–27 000) to 38 000 (32 000–41 000; 
figure 4; appendix p 30). Despite this rise, the global age-
standardised death rate decreased from 0·61 (0·55–0·69) 
per 100 000 population in 1990 to 0·51 (0·42–0·54) per 
100 000 population in 2017, a rate that corresponded with 
a 16·4% (36·0–4·7) decrease in age-standardised death 
Figure 4: Trends from 1990 to 2017 in number and age-standardised death rates of IBD at the global level
Error bars indicate the 95% uncertainty interval (UI) for number of deaths. Shading indicates the 95% UI for the age-standardised death rate. IBD=inflammatory bowel disease.
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rate over the study period (appendix p 30). The total 
number of deaths caused by IBD constituted 0·07% 
(0·06–0·07) of total all-cause deaths in 2017 (estimates 
available through the GBD results tool). In 2017, the 
number of deaths from IBD was highest in females aged 
85–89 years and males aged 80–84 years, whereas the 
age-specific rate of death was highest in the group aged 
95 years and older for both sexes (appendix p 3).
The total YLDs attributed to IBD almost doubled over 
the study period, from 0·56 million (95% UI 0·39–0·77) 
in 1990 to 1·02 million (0·71–1·38) in 2017 (estimates 
available through the GBD results tool). However, the 
age-standardised YLDs rate did not have the same sharp 
increase (12·0 [8·4–16·5] per 100 000 population in 
1990 to 12·6 [8·7–17·0] per 100 000 population in 2017). 
The number of YLDs in 2017 peaked in the 50–54 years 
age group (0·12 million [0·08–0·16]; appendix p 4) and 
then declined in the older age groups. Among the 
diseases in the GBD digestive disease category, IBD rose 
in YLD rank (both number of YLDs and age-standardised 
rate) from fifth in 1990 to fourth in 2017, after upper 
digestive diseases, hernia, and cirrhosis (estimates 
available through the online data visualisation tool).
The total YLLs attributed to IBD in 1990 was 0·68 million 
(95% UI 0·54–0·96), which increased to 0·83 million 
(0·71–0·90) in 2017. The age-standardised rates of YLLs 
declined over time for both sexes, from 14·5 YLLs 
(11·8–19·0) per 100 000 population in 1990 to 10·7 YLLs 
(9·1–11·7) per 100 000 population in 2017, for both sexes 
combined. In 2017, the highest number of YLLs occurred 
in the group aged 65–69 years (72 000 [60 000–77 000]), 
while the highest number of YLDs occurred in the 
50–54 year age group (119 000 [80 000–163 000]; figure 5). 
The 1–4 year age group had the third highest number of 
For the online results tool see 
http://ghdx.healthdata.org/gbd-
results-tool
For the data visualisation tool 
see https://vizhub.healthdata.
org/gbd-compare/
Figure 5: Global counts and age-specific rates of YLLs and YLDs due to IBD across age groups, 2017
Error bars indicate the 95% uncertainty interval (UI) for YLLs and YLDs. Shading indicates the 95% UI for the rates. YLLs=years of life lost. YLDs=years of life lived with 
disability. IBD=inflammatory bowel disease.
1–4 5–9
10
–14
15
–19
20
–24
25
–29
30
–34
35
–39
40
–4
4
45
–4
9
50
–54
55
–59
60
–6
4
65
–6
9
70
–74
75
–79
80
–8
4
85
–8
9
90
–9
4
≥9
5
Age (years)
0 0
40
60
80
100
120
140200 000
150 000
100 000
50 000
20
To
ta
l Y
LL
s a
nd
 Y
LD
s
YLL and YLD rate (per 100 000 population)
YLD (number, 95% UI)
YLL (number, 95% UI)
YLD (rate, 95% UI)
YLL (rate, 95% UI)
Figure 6: Trends from 1990 to 2017 in age-standardised death rate of IBD in seven GBD super-regions
IBD=inflammatory bowel disease. GBD=Global Burden of Disease, Injuries, and Risk Factors Study.
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YLLs, because each death at a young age results in more 
YLLs than at older ages, but had the second lowest number 
of YLDs (figure 5).
The age-standardised rate of DALYs decreased from 
26·5 (95% UI 21·0–33·0) per 100 000 population in 1990 
to 23·2 (19·1–27·8) per 100 000 population in 2017 
(appendix p 38). The total DALYs caused by IBD increased 
between 1990 (1·25 million [0·97–1·61]) and 2017 
(1·85 million [1·51–2·23]; appendix p 38). Of the total 
DALYs caused by IBD in 2017, 45% were due to YLLs and 
55% were due to YLDs.
In 2017, the highest age-standardised prevalence rate 
among all seven super-regions was observed in the high-
income super-region (206·1 [95% UI 195·3–216·8] per 
100 000 population; appendix p 8). Moreover, this region 
had the highest increase in the age-standardised 
prevalence rate from 1990 to 2017 (31·3% [26·4–36·6]; 
percentage changes for other super-regions available 
from the GBD results tool).
The high-income super-region also had the largest 
increase in age-standardised death rate from 1990 to 2017 
(17·6% [95% UI –35·7 to 34·7]; figure 6). Sub-Saharan 
Africa was the only other super-region to experience an 
increase in age-standardised death rate over the study 
period, a 0·7% (–32·5 to 43·6) increase (figure 6). The 
total number of deaths caused by IBD in the high-income 
super-region increased from 7440 (95% UI 6910–9550) in 
1990 to 16 900 (10 300–18 800) in 2017 (super-region data 
available from the GBD results tool). North Africa and 
the Middle East remained the super-region with the 
lowest number of deaths, with 872 (781–999) deaths in 
2017. The number of deaths was 372 (317–432) in females 
and 500 (436–605) in males. The 2017 age-standardised 
death rate in this super-region was also the lowest 
among all GBD super-regions (0·21 [0·19–0·25] per 
100 000 population). A sharp decrease in the age-
standardised death rate also occurred in southeast Asia, 
east Asia, and Oceania from 1990 to 2017 (figure 6).
High-income North America was the region with the 
highest age-standardised prevalence rate for both sexes 
between 1990 and 2017 (344·8 [95% UI 331·7–359·3] per 
100 000 population in 1990 and 422·0 [398·7–466·1] per 
100 000 population in 2017 for both sexes combined; 
figure 7; appendix pp 11, 22). The lowest age-standardised 
prevalence rate in 2017 was observed in the Caribbean 
(6·7 [6·3–7·2] per 100 000 population; appendix pp 22–29), 
followed by Andean Latin America and the four sub-
Saharan Africa regions.
The western Europe region had the highest age-
standardised death rate in 2017 (0·97 [95% UI 0·54–1·11] 
per 100 000 population), followed by high-income North 
America (0·83 [0·55–0·91] per 100 000 population; 
Figure 7: Age-standardised prevalence rate of IBD globally and for 21 GBD regions by SDI, 1990–2017
For each region, points from left to right depict estimates from each year from 1990 to 2017. IBD=inflammatory bowel disease. GBD=Global Burden of Disease, Injuries, and Risk Factors Study.
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appendix pp 13, 30–37), driven primarily in high-income 
North America by high number of deaths in the USA 
(appendix p 30). Both western Europe (33·6% 
[–37·5 to 59·0]) and high-income North America (36·9% 
[–22·3 to 57·1]) experienced an increase in age-standardised 
death rate over the study period (figure 8). The age-
standardised death rate decreased sharply in east Asia 
(59·6% [66·3–27·3] decrease from 1990 to 2017; appendix 
pp 14, 33). High-income Asia Pacific (0·16 [0·13–0·24] per 
100 000 population), north Africa and the Middle East 
(0·21 [0·19–0·25] per 100 000 population), and Andean 
Latin America (0·26 [0·22–0·29] per 100 000 population) 
had the lowest age-standardised death rate among regions 
in 2017 (figure 8; appendix p 13).
Higher SDI was associated with higher age-standardised 
prevalence rates of IBD, with values that were higher than 
the global rate in the two highest SDI quintiles, and lower 
than the global rate in the three lowest SDI quintiles 
(figure 9). High SDI and low SDI quintiles had the highest 
and lowest age-standardised prevalence rates (213·0 
[95% UI 202·3–223·8] per 100 000 population and 
13·8 [12·6–15·2] per 100 000 population), respectively, in 
2017 (figure 8). By contrast, while the high SDI quintile 
(0·71 [0·44–0·78] per 100 000 population) also had the 
highest age-standardised death rate in 2017, the low SDI 
quintile (0·52 [0·42–0·64]) had the second-highest rate. 
The largest decrease in age-standardised death rate from 
1990 to 2017 occurred in the middle SDI quintile (46·2% 
[51·8–22·4] decrease; GBD results tool).
The age-standardised prevalence rate of IBD in the two 
most populous countries, China and India, were 
136·2 (95% UI 125·4 to 147·4) per 100 000 population and 
16·2 (14·7 to 17·9) per 100 000 pop u lation, respectively, in 
2017 (see appendix p 22–29 for the full national-level data 
for age-standardised prevalence rates). The highest age-
standardised prevalence rate of IBD was observed in 
the USA (464·5 [438·6 to 490·9] per 100 000 population), 
followed by the UK (449·6 [420·6 to 481·6] per 
100 000 population). At a national level, the largest change 
in age-standardised prevalence rate of IBD from 
1990 to 2017 occurred in the Solomon Islands, where the 
age-standardised prevalence rate increased by 139·8% 
(106·3 to 177·7). In 1990, the age-standardised prevalence 
rate of IBD in this country was 10·3 (9·2 to 11·5) per 
100 000 population, increasing to 24·6 (20·7 to 29·5) per 
100 000 population in 2017. Vanuatu had the highest age-
standardised death rate in 2017 (1·8 [0·8 to 3·2] per 
100 000 population), and Singapore had the lowest (0·08 
[0·06 to 0·14] per 100 000 population; appendix pp 17, 
30–37; see appendix pp 30–37 for the full national level 
Figure 8: Age-standardised death rate of IBD globally and for 21 GBD regions by SDI, 1990–2017 
The expected age-standardised death rate in 2017 based solely on SDI is represented by the black line. For each region, points from left to right depict estimates from each year from 1990 to 2017. 
IBD=inflammatory bowel disease. SDI=Socio-demographic Index.
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data for age-standardised death rates). At the national 
level, Italy had the largest increase in age-standardised 
death rate over the study period, from 0·40 (0·34 to 0·63) 
per 100 000 population in 1990 to 0·79 (0·34 to 0·95) per 
100 000 population in 2017—a 99% (–39·4 to 170·6) 
increase. South Korea had the largest decrease in age-
standardised death rate over the study period (77·8% 
[84·6 to 8·7] decrease per 100 000 population (appendix 
pp 18, 30–37). The age-standardised death rate in South 
Korea decreased from 1·62 (0·48 to 2·07) per 
100 000 population in 1990 to 0·36 (0·30 to 0·49) per 
100 000 population in 2017. Age-standardised DALY rates 
caused by IBD in 2017, for 195 countries and territories, 
are presented in figure 10 and in the appendix (pp 38–45).
Discussion
In this study, we used a standardised approach to 
describe burden due to IBD at the global, super-region, 
regional, and national levels. We report that currently, 
approximately nearly 3·9 million females and nearly 
3·0 million males are living with IBD worldwide and the 
number of prevalent cases is on the rise. This is 
important for health-care delivery systems and economies 
in the global context of treating chronic diseases like 
IBD, because standard care for these conditions, 
particularly immunotherapies, is extremely costly.
Historically, IBD has been considered a condition of 
high-income countries.1,10 We found that the region of 
high-income North America, specifically the USA, 
makes a prominent contribution to the global number 
of patients with IBD. The USA had the highest age-
standardised prevalence rate globally, with nearly a 
quarter of total global patients with IBD living there in 
2017. Among European countries, the UK had the 
highest age-standardised prevalence. The prevalence of 
IBD was reported to range from 252 to 439 cases per 
100 000 population in the USA.11 A 2018 systematic 
review3 evaluating more than 200 population-based 
studies reported that the highest prevalence rate of IBD 
occurred in North America. In the UK, a prevalence as 
high as 373 per 100 000 population has been reported.12 
Our estimates confirmed these findings and showed an 
age-standardised prevalence rate of 464·5 (95% UI 
438·6–490·9) per 100 000 population for the USA.
We also noticed a clear trend in prevalence of IBD from 
low to high SDI quintiles, with higher prevalence in 
countries in the high SDI quintile. This pattern was 
preserved over time, suggesting that the burden of IBD 
was consistently greater in countries with a high index of 
development such as the UK, the USA, Canada, and 
Australia. This correlation, suggested by many studies,13–15 
might indicate that there are common environmental 
pressures across these regions that act as important risk 
factors for IBD, although we did not evaluate the role of 
potential risk factors in IBD prevalence for this study. 
These risk factors might include urbanisa tion, more 
hygienic environments, and diets low in dietary fibre 
and high in meat.15,16 Based on the immune disease 
development model, the higher prevalence of IBD among 
people with higher socioeconomic status has been 
suggested to be due to a delay in or low level of exposure to 
common infectious agents during childhood. Conse-
quently, the immune response is altered in genetically 
susceptible individuals.17,18 Therefore, the primary health-
care indicators of high-income and low-income countries 
might be correlated with prevalence rates, because in 
many low-income countries in Asia and Africa, basic 
sanitation is still an issue. The higher prevalence of IBD 
in regions with higher SDI might also be interpreted as an 
indication that individuals with higher socio-demographic 
status are at higher risk of IBD and need more investiga-
tion during their routine check-ups. Another possible 
explanation for the higher prevalence of IBD in higher 
sociodemographic regions might be better access to diag-
nostic testing tools, resulting in higher rates of diagnosis.16
We report an increase in age-standardised prevalence 
rate of IBD in regions that formerly had low prevalence, 
including east and south Asia, Oceania, and sub-
Saharan Africa. It is probable that a combination of 
factors, including improve ments in the socioeconomic 
status of newly industrialised countries, changes in diet 
and other lifestyle changes, improved sanitation, 
changed microbiota, and environmental fac tors, 
increase the risk of developing IBD.10,13,19 Behavi oural 
and environmental factors might play an increasingly 
critical role in the development of IBD.20 Different 
factors that might increase the risk of developing IBD 
include smoking, lifestyle choices, discontinued 
breastfeeding, enteric infections, appen dicectomy, and 
air pollution.20,21 Improvement in access to health-care 
systems, more widely available diagnostic tools, and 
increased awareness on the part of both patients and 
physicians19 might also contribute to higher rates of 
diagnosis.
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Figure 9: Trends from 1990 to 2017 in age-standardised prevalence rates of IBD by SDI quintile
IBD=inflammatory bowel disease. SDI=Socio-demographic Index.
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The continuing increase in prevalence of IBD in 
previously low-prevalence areas has important impli-
cations for both health-care providers and those 
responsible for health-care policy planning. Almost three-
quarters of all people (about 3–5 billion) live in developing 
countries.22 Almost 2·7 billion people live in India and 
China. Therefore, even a small increase in the occurrence 
of chronic diseases such as IBD, which has low mortality 
but high disability, could have devastating effects in 
developing countries in the coming years.3 Of note, the 
economic effects of IBD are not limited to its burden on 
health-care systems. A German study23 reported that, each 
year, about 9% and 3% of all German employees with 
IBD had rehabilitation or were granted a disability 
pension, respect ively. More than 50% of the total social 
costs of IBD are indirect costs such as early retirement or 
sick leave.24 Therefore, IBD contributes to an ever-
increasing burden, not only on health-care systems but 
also on the economy as a whole.
We report that the age-specific death rate at the global 
and regional levels attenuated from 1990 to 2017. The 
overall decrease in mortality probably reflects the 
improved survival of patients with IBD, which might be 
due to increased use of immuno modulators, earlier 
introduction of biologi cal agents, improvements in 
surgical techniques, and increased awareness of 
colorectal cancer surveillance.25,26
Because the prevalence of IBD is much lower in low 
SDI countries, we expected a lower age-standardised 
death rate in these countries than in high SDI locations. 
However, the low quality of death registries in these 
countries might be another reason behind the low 
number of reported deaths in low SDI countries. 
Moreover, it is clear that IBD is not an easy disease to 
diagnose—ie, it requires a colonoscopy, and this is not 
available for the majority of people living in low SDI 
countries. It is possible that the fewer reported deaths 
due to IBD in low SDI countries might be due to under-
detection of IBD-related deaths.
Although the fatal burden of IBD remains relatively 
low, the non-fatal burden continues to increase, climbing 
from the fifth-leading cause of YLDs among digestive 
diseases in 1990 to the fourth in 2017. IBD can substantially 
compromise the physical, psychological, familial, and 
social dimensions of life. As a result, the secondary effects 
of the disease can be seen in the increased rates of anxiety, 
depression, and other emotional effects. A 2016 study27 
showed a notable association between symptoms of 
depression and clinical disease activity in patients with 
IBD, regardless of IBD subtypes. However, only IBD-
specific symptoms are accounted for in disability weights 
in GBD, and not the social stigma, depression, anxiety, 
and other inflammatory conditions.
Sex-stratified global and national incidence rates of IBD, 
reported either by GBD or by other studies, are similar, 
suggesting that the disease is not sex-specific.28 However, 
the age-standardised death rate of IBD is lower, but the 
prevalence rate is higher, among females. It is possible that 
differences in environ mental determinants derived from 
biological, social, and economic exposures between males 
Figure 10: Age-standardised DALYs rates from IBD by SDI for 195 countries and territories in 2017
The black line represents the expected age-standardised DALY rate of IBD based solely on SDI. DALY=disability-adjusted life-year. IBD=inflammatory bowel disease. SDI=Socio-demographic Index.
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and females might be responsible for this difference. The 
higher prevalence of smoking, as one of the most 
consistently studied environmental factors of IBD, in 
males compared with females might have contributed to 
the higher mortality rate in male patients.29 Alternatively, 
some studies point to the influence of hormones on the 
brain–gut–microbiota axis as the reason for sex differences 
in IBD prognosis, but the mechanism underlying this 
complex pathophysiology is still not completely 
understood.
As is the case with all GBD research, our study was 
limited by low availability and quality of data, which could 
only partially be overcome by using statistical methods. 
In data-scarce locations, we had to rely on predictive 
covariates and spatiotemporal trends. For non-fatal 
models, for which data were especially scarce, this resulted 
in estimates for some regions being determined entirely 
by global trends and associations with income and health-
care access (in the case of Oceania and western, central, 
and southern sub-Saharan Africa), and by these factors 
plus data for a single country (in the case of eastern sub-
Saharan Africa and South Asia). This is reflected in wider 
UIs in these locations, and suggests extra caution should 
be applied in interpreting estimates for these locations. It 
might also explain an unexpected discrepancy in age-
standardised prevalence rate between China (136·2 [95% UI 
125·4–147·4] per 100 000 population), where we had 
many data inputs, and India (16·2 [14·7–17·9] per 
100 000 population) in 2017, where estimates were heavily 
influenced by a single Nepalese data source. Our results 
for India were lower than previous reports, mainly for the 
northern parts of the country. The age-standardised 
prevalence rate estimates for India also contrast previous 
reports,30–32 suggesting that a single Nepalese study in the 
GBD 2017 database for south Asia may be poorly 
representative of the region. Primary data from these 
previous reports should be incorporated into future rounds 
of GBD to improve these estimates. Likewise, special effort 
should be made to obtain more input data from other data-
scarce regions.
Additionally, some prevalence estimates could have been 
improved by imposing an upper bound on the prior value 
for excess mortality rate or providing data inputs on excess 
mortality to our compartmental models. For example, 
a large population-based study33 in Canada reported a 
prevalence of IBD around 520 per 100 000 population, 
notably higher than the GBD 2017 prevalence estimates, 
which ranged from 46 to 57 cases per 100 000 population; 
this lower estimate was influenced by a high previous 
distribution of excess mortality in our high-income North 
America model, which was overcome by abundant 
prevalence data inputs for the USA, but not by the relatively 
fewer prevalence data inputs for Canada.
 Lastly, because of greater availability of data from 
facilities and insurance claims, we relied on ICD10-based 
diagnosis for our case definition, and used fixed effects 
from our global mixed-effects compartmental model to 
adjust data with other case definitions toward this ref-
erence. In future rounds of GBD, we will use previously 
published estimates of the predictive value of ICD codes 
in administrative data to adjust our administrative data 
inputs toward the magnitude we would expect with 
stringent diagnosis, thus improving the specificity of our 
case definition but maintaining the geographical 
coverage afforded by administrative data. We also hope 
to include an analysis of the burden of IBD that is 
attributable to certain risk factors in future iterations of 
GBD, once the links between IBD and potential risk 
factors are better understood.
The natural course of IBD, with low mortality, as well as 
improved survival, caused an increase in prevalence of 
the disease from 1990 to 2017. In keep with this trend, 
prevalence is expected to continue increasing in the 
future. Rising prevalence, plus the increase in incidence 
in historically low-incidence regions, will have important 
health and economic effects. Our findings could be useful 
for health service planners and policy makers to justify 
and prioritise resource allocation to be able to respond to 
the growing number of patients with IBD. This study will 
motivate health planners to develop cost-effective and 
simple community-based interventions for implemen-
tation by health-care professionals at the primary-care 
level. This is necessary because IBD can last for many 
years and the ageing population is increasing.
We emphasise that understanding the shared and 
different environmental determinants of IBD across 
various regions is essential to implement interventions 
that will slow down the rising global burden of IBD.
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